The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
High-density lipoprotein as a modulator of platelet and coagulation responses
Abstract
Platelets and coagulation factors are involved in the process of haemostasis, which ensures undisturbed blood flow upon vessel wall damage. However, excessive platelet aggregation and/or coagulation may lead to arterial or venous thrombosis. Pro-atherogenic lipoproteins, including native and oxidized low-density lipoprotein (LDL), are associated with an increased susceptibility to thrombosis. In contrast, numerous epidemiological studies have established an inverse correlation between high-density lipoprotein (HDL) levels and the risk for thrombosis. In addition to its role in reverse cholesterol transport, HDL also interacts with platelets, the coagulation cascade, and the vascular endothelium. Native HDL prevents platelet hyperreactivity by limiting intraplatelet cholesterol overload, as well as by modulating platelet signalling pathways after binding platelet HDL receptors such as scavenger receptor class B type I (SR-BI) and apoER2'. The antithrombotic properties of native HDL are also related to the suppression of the coagulation cascade and stimulation of clot fibrinolysis. Furthermore, HDL stimulates the endothelial production of nitric oxide and prostacyclin, which are potent inhibitors of platelet activation. Thus, HDL's antithrombotic actions are multiple and therefore, raising HDL may be an important therapeutic strategy to reduce the risk of arterial and venous thrombosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Platelet Activation and Atherothrombosis
Davì, G., & Patrono, C. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071014 · Cited by 2,135
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Genetic Variant of the Scavenger Receptor BI in Humans
Vergeer, M., Korporaal, S. J. A., Franssen, R., Meurs, I., Out, R., Hovingh, G. K., Hoekstra, M., Sierts, J. A., Dallinga-Thie, G. M., Motazacker, M. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0907687 · Cited by 317
Self-citationCaughey, G. E., Cleland, L. G., Penglis, P. S., Gamble, J. R., & James, M. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.5.2831 · Cited by 283
Cooney, M. T., Dudina, A., De Bacquer, D., Wilhelmsen, L., Sans, S., Menotti, A., De Backer, G., Jousilahti, P., Keil, U., Thomsen, T., et al. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.02.041 · Cited by 250
Apolipoprotein E Inhibits Platelet Aggregation through the L-Arginine:Nitric Oxide Pathway
Riddell, D. R., Graham, A., & Owen, J. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.1.89 · Cited by 209
High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality
Silbernagel, G., Schottker, B., Appelbaum, S., Scharnagl, H., Kleber, M. E., Grammer, T. B., Ritsch, A., Mons, U., Holleczek, B., Goliasch, G., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht343 · Cited by 123
Identification and characterization of LRP8 (apoER2) in human blood platelets
Riddell, D. R., Vinogradov, D. V., Stannard, A. K., Chadwick, N., & Owen, J. S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34910-5 · Cited by 106
Cited by
A robust and efficient method for Mendelian randomization with hundreds of genetic variants
Burgess, S., Foley, C. N., Allara, E., Staley, J. R., & Howson, J. M. M. (2020) · Nature Communications · doi:10.1038/s41467-019-14156-4 · Cited by 681
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 407
The HDL proteome watch: compilation of studies leads to new insights on HDL function
Davidson, W. S., Shah, A. S., Sexmith, H., & Gordon, S. M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2021.159072 · Cited by 107
Morris, G., Puri, B. K., Bortolasci, C. C., Carvalho, A., Berk, M., Walder, K., Moreira, E. G., & Maes, M. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.037 · Cited by 84
Jialal, I., Jialal, G., & Adams‐Huet, B. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3403 · Cited by 83
Metadata
- Authors
- van der Stoep, M., Korporaal, S. J. A., & Van Eck, M.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-06-01
- Volume
- 103
- Issue
- 3
- Pages
- 362-371
- ISSN
- 0008-6363 (ISSN-L)
- OpenAlex
- W2133454964
- Cited by
- 191
- References
- 10
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-density lipoprotein as a modulator of platelet and coagulation responses. https://app.cochat.ai/papers/10.1093/cvr/cvu137
- The paper
- van der Stoep, M., Korporaal, S. J. A., & Van Eck, M. (2014). High-density lipoprotein as a modulator of platelet and coagulation responses. Cardiovascular Research. https://doi.org/10.1093/cvr/cvu137
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.